These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25270328)

  • 1. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
    Fofana DB; Soulie C; Maiga AI; Fourati S; Malet I; Wirden M; Tounkara A; Traore HA; Calvez V; Marcelin AG; Lambert-Niclot S
    J Antimicrob Chemother; 2013 Nov; 68(11):2515-20. PubMed ID: 23833185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
    Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
    J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of HIV type 1 strains from newly infected untreated patients in cyprus: high genetic diversity and low prevalence of drug resistance.
    Kousiappa I; van de Vijver DA; Demetriades I; Kostrikis LG
    AIDS Res Hum Retroviruses; 2009 Jan; 25(1):23-35. PubMed ID: 19182918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
    Carmona R; Pérez-Alvarez L; Muñoz M; Casado G; Delgado E; Sierra M; Thomson M; Vega Y; Vázquez de Parga E; Contreras G; Medrano L; Nájera R
    J Clin Virol; 2005 Mar; 32(3):248-53. PubMed ID: 15722032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon.
    Turriziani O; Montagna C; Falasca F; Bucci M; Russo G; Lichtner M; Sobze MS; Vullo V; Pistello M; Antonelli G
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1729-33. PubMed ID: 22214532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance.
    Muniz CP; Soares MA; Santos AF
    J Antimicrob Chemother; 2014 Oct; 69(10):2741-5. PubMed ID: 24948706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.
    Fleury HJ; Toni T; Lan NT; Hung PV; Deshpande A; Recordon-Pinson P; Boucher S; Lazaro E; Jauvin V; Lavignolle-Aurillac V; Lebel-Binay S; Cheret A; Masquelier B
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):357-66. PubMed ID: 16623640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.
    Van Laethem K; Schrooten Y; Lemey P; Van Wijngaerden E; De Wit S; Van Ranst M; Vandamme AM
    J Virol Methods; 2005 Jan; 123(1):25-34. PubMed ID: 15582695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
    van de Vijver DA; Wensing AM; Angarano G; Asjö B; Balotta C; Boeri E; Camacho R; Chaix ML; Costagliola D; De Luca A; Derdelinckx I; Grossman Z; Hamouda O; Hatzakis A; Hemmer R; Hoepelman A; Horban A; Korn K; Kücherer C; Leitner T; Loveday C; MacRae E; Maljkovic I; de Mendoza C; Meyer L; Nielsen C; Op de Coul EL; Ormaasen V; Paraskevis D; Perrin L; Puchhammer-Stöckl E; Ruiz L; Salminen M; Schmit JC; Schneider F; Schuurman R; Soriano V; Stanczak G; Stanojevic M; Vandamme AM; Van Laethem K; Violin M; Wilbe K; Yerly S; Zazzi M; Boucher CA
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):352-60. PubMed ID: 16540937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
    Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.